Scholar Rock Holding Corp (SRRK): Total Liabilities
$158.78M
As of 2025-12-31
$269.76M
As of 2026-06-30
+17.5%
3-year compound annual growth
+4.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $158.78M | +49.4% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $106.29M | +23.9% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $85.82M | -12.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $97.93M | -26.0% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $132.37M | +3.8% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $127.53M | +52.8% | 2022-03-07, Balance as of period end |
| 2019-12-31 | $83.48M | +11.7% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $74.71M | n/m | 2020-03-12, Balance as of period end |
| 2017-12-31 | $5.93M | n/a | 2019-03-19, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $158.78M | +49.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $11.18B | -1.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
Compare SRRK, VXRT, RGEN, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗